• Conference
  • Earn CE
  • Free Samples
  • Magazine
  • Subscribe
  • Videos
    • Recent Quotes
    My Watchlist
    Indicators
    Dental Market Index
    Markets
    Stocks
    ETFs
    Tools
    Markets:
    Overview
    News
    Currencies
    International
    Treasuries

    Nexalin Technology, Inc. - Common Stock (NQ:NXL)

    0.4439 -0.0020 (-0.45%)
    Streaming Delayed Price Updated: 11:09 AM EST, Feb 13, 2026 Add to My Watchlist
    Quote
    Overview Detailed Quote Charting Historical Prices
    News
    All News News Headlines Press Releases
    Research
    Quarterly Reports Insider Filings Other Filings

    Price and Volume

    Detailed Quote
    Volume 37,955
    Open 0.4571
    Bid (Size) 0.4300 (100)
    Ask (Size) 0.4440 (200)
    Prev. Close 0.4459
    Today's Range 0.4220 - 0.4799
    52wk Range 0.4448 - 3.540
    Shares Outstanding N/A
    Dividend Yield N/A
    Chart for (: )
    Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

    Top News

    More News
    News headline image
    Nexalin Technology and First Phosphate Interviews to Air on the RedChip Small Stocks, Big Money(TM) Show on Bloomberg TV
    Via ACCESS Newswire
    Unusual volume stocks in Friday's session ↗
    Via Chartmill

    Performance

    YTD
    -23.8%
    -23.8%
    1 Month
    -34.7%
    -34.7%
    3 Month
    -62.1%
    -62.1%
    6 Month
    -44.9%
    -44.9%
    1 Year
    -86.0%
    -86.0%

    More News

    Read More
    News headline image
    Nexalin Launches NeuroCare®, an AI-Driven Virtual Clinic Designed to Transform Access for Patients with Alzheimer’s, Mood Disorders, TBI & PTSD Care
    From Nexalin Technology, Inc.
    Via GlobeNewswire
    Discover the top movers in Thursday's pre-market session. ↗
    Via Chartmill
    Top movers in Tuesday's pre-market session ↗
    Via Chartmill
    News headline image
    Nexalin Highlights its Expanding Body of Peer-Reviewed Neuroimaging Research Confirming its DIFS™ Technology as the Leader in Evidenced-Based Non-Invasive Brain Stimulation
    From Nexalin Technology, Inc.
    Via GlobeNewswire
    News headline image
    Nexalin Technology Receives Nasdaq Listing Status Notification
    From Nexalin Technology, Inc.
    Via GlobeNewswire
    News headline image
    Published Peer-Reviewed Study Demonstrates Nexalin’s DIFS™ Neurostimulation Improves Attention and Normalizes Brain Activity in Patients with ADHD
    From Nexalin Technology, Inc.
    Via GlobeNewswire
    News headline image
    Nexalin Technology Completes FDA Q-Submission Meeting for Gen-2 SYNC™ Neurostimulation Console in Alzheimer’s Disease Program
    From Nexalin Technology, Inc.
    Via GlobeNewswire
    News headline image
    Join Nexalin Technology’s Exclusive Live Investor Webinar and Q&A Session on December 4
    From Nexalin Technology, Inc.
    Via GlobeNewswire
    News headline image
    Wondering what's happening in today's pre-market session? ↗
    Via Chartmill
    News headline image
    Nexalin’s 15 Milliamp Neurostimulation Device Demonstrates Promising Results in Treating Gambling Disorder with Alcohol Use Comorbidity
    From Nexalin Technology, Inc.
    Via GlobeNewswire
    News headline image
    Nexalin Technology Appoints Carmi Masha Technologies Ltd. as Exclusive Distributor in Israel
    From Nexalin Technology, Inc.
    Via GlobeNewswire
    News headline image
    Nexalin Technology’s Q-Submission for Gen-2 SYNC Accepted by U.S. FDA for the Treatment of Alzheimer’s Disease and Dementia
    From Nexalin Technology, Inc.
    Via GlobeNewswire
    News headline image
    Nexalin Technology Announces Regulatory Approval to Sell Gen 2 SYNC, 15 mA Neurostimulation DIFS™ Device in Israel
    From Nexalin Technology, Inc.
    Via GlobeNewswire
    News headline image
    Nexalin’s DIFS™ Neurostimulation Shows Cognitive and Brain Network Improvements in Alzheimer’s and Dementia Across Three Peer-Reviewed Studies
    From Nexalin Technology, Inc.
    Via GlobeNewswire
    News headline image
    Nexalin Technology and BioVie Interviews to Air on the RedChip Small Stocks, Big Money(TM) Show on Bloomberg TV
    Via ACCESS Newswire
    News headline image
    Nexalin Technology Expands Scientific Advisory Board with Appointment of Dr. Robert Rothstein to Support Alzheimer’s and Traumatic Brain Injury Programs
    From Nexalin Technology, Inc.
    Via GlobeNewswire
    News headline image
    Nexalin Technology Announces Attendance at the 2025 Maxim Growth Summit
    From Nexalin Technology, Inc.
    Via GlobeNewswire
    News headline image
    12 Health Care Stocks Moving In Thursday's Intraday Session ↗
    Via Benzinga
    News headline image
    Gapping stocks in Thursday's session ↗
    Via Chartmill
    News headline image
    Which stocks are moving before the opening bell on Thursday? ↗
    Via Chartmill
    News headline image
    12 Health Care Stocks Moving In Thursday's Pre-Market Session ↗
    Via Benzinga
    News headline image
    Why Richardson Electronics Shares Are Trading Higher By Over 20%; Here Are 20 Stocks Moving Premarket ↗
    Via Benzinga
    News headline image
    12 Health Care Stocks Moving In Wednesday's After-Market Session ↗
    Via Benzinga

    Frequently Asked Questions

    Is Nexalin Technology, Inc. - Common Stock publicly traded?
    Yes, Nexalin Technology, Inc. - Common Stock is publicly traded.
    What exchange does Nexalin Technology, Inc. - Common Stock trade on?
    Nexalin Technology, Inc. - Common Stock trades on the Nasdaq Stock Market
    What is the ticker symbol for Nexalin Technology, Inc. - Common Stock?
    The ticker symbol for Nexalin Technology, Inc. - Common Stock is NXL on the Nasdaq Stock Market
    What is the current price of Nexalin Technology, Inc. - Common Stock?
    The current price of Nexalin Technology, Inc. - Common Stock is 0.4439
    When was Nexalin Technology, Inc. - Common Stock last traded?
    The last trade of Nexalin Technology, Inc. - Common Stock was at 02/13/26 11:09 AM ET
    Stock Quote API & Stock News API supplied by www.cloudquote.io
    Quotes delayed at least 20 minutes.
    By accessing this page, you agree to the Privacy Policy and Terms Of Service.
    © 2025 FinancialContent. All rights reserved.